Four patents currently held, every record listed here
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jul 2031. from the record
Of the 1 now held by other companies, 1 name Genmab B.V. as their current owner. Each row says so.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Jul 2031
Next term end
4
Patent families
When these terms end
Each bar runs from grant to computed term end. 2015 to 2041.
US 9,120,856
ANTI-CD19 Antibody Having Adcc Function with Improved Glycosylation Profile
Jul 18, 2031
US 9,611,327
ANTI-DR5 Family Antibodies, Bispecific or Multivalent ANTI-DR5 Family Antibodies and Methods of Use Thereof
Oct 31, 2033
US 11,634,488
Treatment of B Cell Malignancies Using Afucosylated Pro-Apoptotic ANTI-CD19 Antibodies in Combination with Anti CD20 Antibodies or Chemotherapeutics
Mar 10, 2039
202020252030203520402041
Every computed term in this portfolio is shown above.Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Jul 2031 · High confidence
Also notable
Ends Oct 2035 · High confidence
Also notable
Ends Mar 2039 · High confidence
Also notable
Ends Nov 2041 · High confidence
ANTI-CD19 Antibody Having Adcc Function with Improved Glycosylation Profile
US 9,120,856
Granted 2015 and renewed at every maintenance window due so far. Protection runs to 2031.
ANTI-CK8 Antibodies for Use in the Treatment of Colorectal Cancers
US 10,533,046
Granted 2020. Computed term ends 2035.
Treatment of B Cell Malignancies Using Afucosylated Pro-Apoptotic ANTI-CD19 Antibodies in Combination with Anti CD20 Antibodies or Chemotherapeutics
US 11,634,488
Granted 2023. Computed term ends 2039.
ANTI-CD5 Antibodies and Methods of Use Thereof
US 12,077,597
Granted 2024. Too new for citation comparison; protection runs to 2041.
Formerly held, still cited
Notable
Ends Oct 2033 · High confidence
Granted 2017 and renewed at every maintenance window due so far. Protection runs to 2033.
now held by Genmab B.V.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Mar 1, 2027The maintenance fee for ANTI-CD19 Antibody Having Adcc Function with Improved Glycosylation Profile (US 9,120,856) comes due Mar 1, 2027. Unpaid by Sep 1, 2027, it lapses early.
- 1 fee due Jul 14, 2027The maintenance fee for ANTI-CK8 Antibodies for Use in the Treatment of Colorectal Cancers (US 10,533,046) comes due Jul 14, 2027. Unpaid by Jan 14, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The 3 largest of its 4 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Showing 1 to 4 of 4
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,120,856 | ANTI-CD19 Antibody Having Adcc Function with Improved Glycosylation Profile held by International-Drug-Development Biotech, Ucbl Universite Claude Bernard de Lyon 1 and Hospices Civils de Lyon In force · High confidence | In force | High confidence | |
| US 10,533,046 | ANTI-CK8 Antibodies for Use in the Treatment of Colorectal Cancers held by International - Drug - Development - Biotech, Universite Claude Bernard Lyon 1, Hospices Civils de Lyon, Centre National de la Recherche Scientifique (CNRS), Institut National de la Sante et de la Recherche Medicale (Inserm) and Centre Leon Berard In force · High confidence | In force | High confidence | |
| US 11,634,488 | Treatment of B Cell Malignancies Using Afucosylated Pro-Apoptotic ANTI-CD19 Antibodies in Combination with Anti CD20 Antibodies or Chemotherapeutics In force · High confidence | In force | High confidence | |
| US 12,077,597 | ANTI-CD5 Antibodies and Methods of Use Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 4: 1 patent in force now held by others · 2 patents ended · 4 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.